Bernstein Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $1070

Benzinga · 01/07 17:16
Bernstein analyst William Pickering maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and lowers the price target from $1110 to $1070.